Climb Bio, Inc. (CLYM) · Oct 26, 2026 · Other events

Climb Bio Phase 2 data clear pMN bar, higher dose unproven

Above the bar — 70% mean PLA2R reduction; 38% immunologic remission at Week 12

Climb Bio’s Phase 2 data show meaningful PLA2R reduction and immunologic remission for budoprutug, but the key higher-dose readout is still ahead.

Climb Bio is a clinical-stage biotech advancing budoprutug across kidney and other B-cell-mediated diseases, while separately developing CLYM116 for IgA nephropathy; the company had already framed 2026 as a data-heavy year, with initial PrisMN results expected in the second half or fourth quarter.

The pMN readout is better than a routine first look. In the 200 mg cohort, mean PLA2R antibodies fell 70% by Week 12 and 5 of 13 patients achieved immunologic remission, with an 80% mean reduction in the lower-baseline subgroup. That is directionally consistent with the company’s prior Phase 1b signal rather than a wholly new efficacy claim, but it confirms activity in a larger Phase 2 cohort containing treatment-experienced patients with substantial proteinuria. (PrisMN Phase 2 data)

Measure	Initial result	Why it matters
Mean PLA2R reduction, 200 mg, Week 12	70%	Strong early autoantibody signal (PrisMN Phase 2 data)
Immunologic remission, 200 mg, Week 12	5/13, or 38%	Confirms biological activity, but from a small open-label cohort (PrisMN Phase 2 data)
Mean PLA2R reduction, baseline <175 RU/mL	80%	Suggests baseline antibody burden may influence response (PrisMN Phase 2 data)
CD20+ B-cell suppression, Week 4	98% at 600 mg vs. 74% at 200 mg	Supports dose escalation, not clinical efficacy yet (PrisMN Phase 2 data)
Follow-up available	12 weeks at 200 mg; 6 weeks at 600 mg	Clinical remission and durability remain immature (Item 8.01)

The dose-selection story is the real strategic update. Proteinuric patients clear budoprutug at least twice as fast as non-proteinuric individuals, giving Climb Bio a pharmacokinetic rationale for testing 600 mg and 1,000 mg rather than treating the 200 mg result as the final regimen. The 600 mg cohort is producing deeper early B-cell suppression, but that is still a pharmacodynamic signal, not proof that higher dosing improves kidney outcomes. 〔0〕 (Population PK analysis; PrisMN Phase 2 data)

Safety is supportive but not yet a differentiator. Through the disclosed follow-up, no treatment-related serious adverse events, treatment discontinuations, or deaths were reported, and most adverse events were mild to moderate. 〔1〕 That keeps the program moving into higher doses, although the 600 mg safety window is based on only six weeks of follow-up and the filing does not provide mature renal-response data.

The minimal-change-disease case expands the narrative, not the evidence base. One patient remaining in steroid-free remission for three years is encouraging for broader glomerular-disease development, but a single case cannot materially validate a second indication. 〔2〕 (Exhibit 99.1, MCD case study)

Bottom line: This is a credible Phase 2 confirmation that budoprutug is biologically active in pMN and that higher dosing is rational. It advances the program, but the decisive evidence—durable proteinuria improvement and whether 600 mg or 1,000 mg improves on the low-dose signal—remains ahead in 2027.

What to watch next

PrisMN higher-dose and Week 48 data, 2027

Original filing on SEC EDGAR

More Climb Bio, Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Climb Bio Phase 2 data clear pMN bar, higher dose unproven

What to watch next

More Climb Bio, Inc. news

Breaking down Wall Street's information edge.